Chargement en cours...
729. Real World Efficacy of Bezlotoxumab for Prevention of Clostridioides Difficile Recurrence in Immunosuppressed Patients
BACKGROUND: Bezlotoxumab has been shown to prevent recurrent episodes of C. difficile infection (CDI) in high risk patients. Current studies define therapeutic efficacy within the first 12 weeks when the risk of recurrence is greatest. However, the risk of recurrent CDI can occur beyond the 12-week...
Enregistré dans:
| Publié dans: | Open Forum Infect Dis |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7777471/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.921 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|